引言:辅助生殖技术附加项目能否坦诚以对
本文为《Views and Reviews》系列引言,讨论体外受精周期中附加项目(add-ons)的现状与证据问题。文中指出患者常面对众多附加项目菜单式选择,系列文章总体结论是:尽管为确立附加项目获益付出相当努力,但就活产结局而言数据仍匮乏。
要点
- 附加项目已成为体外受精周期临床景观的一部分。
- 患者通常面对菜单式附加项目供选择。
- 就活产结局而言,附加项目获益的数据仍匮乏。
核心结论
- 系列文章总体结论是:尽管为确立附加项目获益付出相当努力,但考虑活产结局时数据仍匮乏。
研究设计与样本
- 本文为《Views and Reviews》系列引言,讨论附加项目的各个方面。
主要发现
- 自体外受精早期以来,生育服务一直在寻求提高成功率。
- 目前患者通常面对菜单式附加项目供选择,其驱动力是希望给患者最佳成为父母的机会。
- 该系列并非穷尽性的,系列筹备完成时已有关于细胞因子作为附加项目的新研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adjuncts, more often known as add-ons, are now part of the landscape of an in vitro fertilization cycle. Since the early days of in vitro fertilization, fertility services have rightly been seeking improved success rates. At present there are a multitude of choices for patients who are usually presented with a menu of add-ons to choose from. This is driven by the desire to give patients the best chances of becoming parents. This Views and Reviews series discusses all aspects of add-ons. It is not exhaustive as even as we are finishing the preparation of the series, there is a new study about the use of cytokines as an add-on. The overall conclusion from this series of articles is that despite considerable efforts to establish benefits with add-ons that there is a paucity of data when we consider the outcome of live birth.
引用
- Farquhar C. Introduction: Add-ons for assisted reproductive technology: can we be honest here? Fertil Steril. 2019. PMID: 31843097. doi:10.1016/j.fertnstert.2019.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。